OrthoPediatrics (KIDS) Projected to Post Quarterly Earnings on Tuesday

Key Points

• OrthoPediatrics (KIDS) is set to announce its Q2 2025 earnings on August 5th, with analysts predicting a loss of $0.17 per share and revenue of $61.40 million.
• In the previous quarter, the company reported a loss of $0.39 per share, missing estimates, while revenue beat expectations at $52.41 million.
• OrthoPediatrics currently holds a market capitalization of $543.85 million, and analysts maintain a consensus rating of "Moderate Buy" with an average price target of $35.83.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) is expected to announce its Q2 2025 earnings results after the market closes on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $61.40 million for the quarter. OrthoPediatrics has set its FY 2025 guidance at EPS.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.13). The business had revenue of $52.41 million for the quarter, compared to analysts' expectations of $51.68 million. OrthoPediatrics had a negative return on equity of 7.03% and a negative net margin of 19.15%. On average, analysts expect OrthoPediatrics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

OrthoPediatrics Price Performance

KIDS traded down $0.08 during midday trading on Friday, hitting $20.64. The stock had a trading volume of 74,585 shares, compared to its average volume of 198,724. The company has a market cap of $501.35 million, a P/E ratio of -11.79 and a beta of 1.10. The business has a fifty day moving average of $21.52 and a 200 day moving average of $22.95. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.99 and a current ratio of 6.19. OrthoPediatrics has a 1 year low of $19.51 and a 1 year high of $33.14.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of OrthoPediatrics by 6.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company's stock worth $246,000 after purchasing an additional 645 shares during the period. Jane Street Group LLC purchased a new position in shares of OrthoPediatrics in the 1st quarter worth approximately $389,000. Goldman Sachs Group Inc. boosted its holdings in OrthoPediatrics by 112.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 200,439 shares of the company's stock valued at $4,937,000 after acquiring an additional 106,041 shares during the period. Finally, Millennium Management LLC boosted its holdings in OrthoPediatrics by 55.3% during the 1st quarter. Millennium Management LLC now owns 656,578 shares of the company's stock valued at $16,172,000 after acquiring an additional 233,873 shares during the period. Institutional investors own 69.05% of the company's stock.

Wall Street Analyst Weigh In

KIDS has been the subject of a number of recent analyst reports. Piper Sandler decreased their target price on OrthoPediatrics from $40.00 to $30.00 and set an "overweight" rating for the company in a report on Thursday, May 8th. Needham & Company LLC reissued a "buy" rating and issued a $42.00 target price on shares of OrthoPediatrics in a research note on Thursday, May 8th. Wall Street Zen cut OrthoPediatrics from a "hold" rating to a "sell" rating in a research report on Friday, July 18th. BTIG Research reissued a "buy" rating on shares of OrthoPediatrics in a research report on Monday, July 14th. Finally, Lake Street Capital began coverage on OrthoPediatrics in a research report on Monday, April 7th. They issued a "buy" rating and a $37.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $35.83.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.